<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">16413170</PMID>
      <DateCompleted>
        <Year>2006</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>01</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">0920-1211</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>68 Suppl 2</Volume>
            <PubDate>
              <Year>2006</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Epilepsy research</Title>
          <ISOAbbreviation>Epilepsy Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Introduction to zonisamide.</ArticleTitle>
        <Pagination>
          <StartPage>S3</StartPage>
          <EndPage>S9</EndPage>
          <MedlinePgn>S3-9</MedlinePgn>
        </Pagination>
        <Abstract>
          <AbstractText>Zonisamide (Zonegran), a novel antiepileptic drug (AED) approved recently in Europe as adjunctive therapy for refractory partial seizures in adults, has been used extensively in Japan and the United States. A substantial body of clinical experience has accumulated over a 14-year period, allowing the properties and pharmacologic/clinical profiles of zonisamide to be clearly defined. Zonisamide is structurally distinct from other AEDs and has multiple and complementary mechanisms of action, which likely contribute to its efficacy across a broad range of epilepsy types. Zonisamide has a long T1/2 enabling once-daily dosing, linear pharmacokinetics and minimal interaction with other drugs; plasma levels of commonly administered AEDs and oral contraceptives are unaffected by concomitant zonisamide. Effective control of partial seizures (up to 51% decrease in seizure frequency) is attained at doses of &gt;or=300 mg/day, and optimal titration and maintenance dosing schedules have been established. The adverse event profile is well defined; in common with most AEDs, most adverse events are central nervous system-related (e.g. somnolence, dizziness, tiredness). Adverse events may be minimised with appropriate patient management. Zonisamide therefore has many characteristics considered desirable in an AED and represents a valuable addition to the therapeutic options for treating epilepsy in Europe.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Baulac</LastName>
            <ForeName>Michel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, University of Paris 6, Bat. Paul Castaigne, Hopital de la Pitie-Salpetriere, 47 Bld de l'Hopital, 75013 Paris, France. michel.baulac@psl.ap-hop-paris.fr</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2006</Year>
          <Month>01</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Epilepsy Res</MedlineTA>
        <NlmUniqueID>8703089</NlmUniqueID>
        <ISSNLinking>0920-1211</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>459384H98V</RegistryNumber>
          <NameOfSubstance UI="D000078305">Zonisamide</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004828" MajorTopicYN="N">Epilepsies, Partial</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000078305" MajorTopicYN="N">Zonisamide</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <NumberOfReferences>48</NumberOfReferences>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2005</Year>
          <Month>9</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2005</Year>
          <Month>11</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2005</Year>
          <Month>11</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2006</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2006</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2006</Year>
          <Month>1</Month>
          <Day>18</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">16413170</ArticleId>
        <ArticleId IdType="doi">10.1016/j.eplepsyres.2005.11.004</ArticleId>
        <ArticleId IdType="pii">S0920-1211(05)00296-2</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
